GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are helping millions lose weight and improve metabolic health. But could they also reshape consumer behaviour? This is VANCOLOUR host Mo Amir speaks with Leger Executive Vice President Steve Mossop about new data showing how people taking these medications are reshaping spending habits — from the grocery store to other unexpected parts of the economy. If these “miracle drugs” keep growing in popularity, what industries could be affected positively and negatively?
Recorded: March 9, 2026